Genotype-Guided Use of P2Y12 Inhibitors: A Review of Current State of the Art

The pharmacodynamics of the purinergic receptor type Y, subtype 12 (P2Y12) inhibitors has evolved. Our understanding of the metabolism of P2Y12 inhibitors has revealed polymorphisms that impact drug metabolism and antiplatelet efficacy, leading to genetic testing guided therapy. In addition, assays...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-abcha, Abdullah, Radwan, Yasser, Blais, Danielle, Mazzaferri, Ernest L., Boudoulas, Konstantinos Dean, Essa, Essa M., Gumina, Richard J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983962/
https://www.ncbi.nlm.nih.gov/pubmed/35402528
http://dx.doi.org/10.3389/fcvm.2022.850028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983962/
https://www.ncbi.nlm.nih.gov/pubmed/35402528
http://dx.doi.org/10.3389/fcvm.2022.850028

Ejemplares similares